The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case–control studies

Cancer Cell International

Wen-Li Ma¹  Ling Jiang¹  Wen-Ling Zheng¹  Yan-Bin Song¹  Ling-Hui Wang¹ 

[1] Biochemistry and Molecular Biology Director, Institute of Genetic Engineering, Southern Medical University, Guangzhou, 510515, People’s Republic of China

关键词: Meta-analysis;    Cancer risk;    Polymorphism;    MDR1;   

Others  :  793837
DOI  :  10.1186/1475-2867-13-46

 received in 2012-12-11, accepted in 2013-04-23,  发布年份 2013

【 摘 要 】

Background

The multidrug resistance (MDR) 1 gene encodes a 170-kDa membrane transporter called P-glycoprotein, which plays an important role in protecting cells against lipophilic xenobiotics by the way of an ATP-dependent cellular efflux mechanism. Three polymorphisms of MDR1, 3435C > T located in exon 26, 1236C > T in exon 12 and 2677G > T/A in exon 21 were the most extensively studied and were identified functionally important and ethnically diverse mapping to the gene region. Considering the potential influence of altering MDR1 activity, it is plausible that MDR1 polymorphisms might play a role in the development of cancer. Although the effects of MDR1 polymorphisms on susceptibility to human cancer have been investigated in many studies, the results still remain conflicting.

Methods

To resolve these conflicts, we performed a quantitative synthesis of the association between these three polymorphisms and cancer risk, including 52 studies (15789 cases and 20274 controls) for 3435C > T polymorphism, 10 studies (2101 cases and 2842 controls) for 1236C > T polymorphism and 18 studies (3585 cases and 4351 controls) for 2677G > T/A polymorphism.

Results

The stratified analyses for 3435C > T polymorphism, individuals with T-allele in 3435C > T had significantly higher ALL risks (TT versus CC: OR =1.286, 95% CI =1.123-1.474); significantly elevated risks were observed among Caucasian populations (TT versus CC: OR =1.276, 95% CI =1.112-1.464). When restricting the analysis to the source of controls, we found that HB (hospital-based) genetic models had higher risks (TT versus CC: OR =1.307, 95% CI =1.046-1.632), as well as in PB (population-based) genetic models (TT versus CC: OR =1.294, 95% CI =1.079-1.55).

The T/A-allele frequency of 2677G > T/A polymorphism was associated with higher risk of cancer (TT + TA + AA vs. GG: OR =1.348, 95% CI =1.031-1.762), significantly elevated risks were observed among Asian populations (TT + TA + AA vs. GG: OR =1.642, 95% CI =1.340-2.012), and elevated risks could be associated with PB models (TT + TA + AA vs. GG: OR =1.641, 95% CI =1.018-2.646).

Conclusions

Our meta-analysis suggested that 3435C > T polymorphism and 2677G > T/A polymorphism were associated with cancer risk when all studies were pooled together, while 1236C > T polymorphism not.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Laura M, Hodges SMM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB: Very important pharmacogene summary: ABCB1 (MDR1, Pglycoprotein). Pharmacogenet Genomics 2011, 21(3):152-161.
• [2]Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL: MDR1 Gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 2007, 16:1172-1177.
• [3]Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398.
• [4]Schinkel AH: The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997, 8:161-170.
• [5]Hattori H, Suminoe A, Morimasa W, Yuhki K, Kimitoshi K, Okamura J, Toshiro H, Akinobu M: Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk Res 2007, 31:1633-1640.
• [6]Wang BL, Zhai HY, Chen BY, Zhai SP, Yang HY, Chen XP, et al.: Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat Dis Int 2004, 3:296-299.
• [7]Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, et al.: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991, 51:2720-2726.
• [8]Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 1987, 236:1120-1122.
• [9]Mochida Y, Taguchi K, Taniguchi S, Tsuneyoshi M, Kuwano H, Tsuzuki T, Michihiko K, Morimasa W: The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+)mice. Carcinogenesis 2003, 24:1219-1224.
• [10]Yamada T, Mori Y, Hayashi R, Takada M, Ino Y, Naishiro Y, Tadashi K, Setsuo H: Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res 2003, 63:895-901.
• [11]Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
• [12]Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001, 69:169-174.
• [13]Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG, Pharmacogenetics of Membrane Transporters Investigators: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13:481-494.
• [14]Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P- glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
• [15]Ji-Ye Y, Qiong H, Youyun Y, Jian-Ting Z, Mei-Zuo Z, Hong-Hao Z, Zhao-Qian L: Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 2009 March, 19(3):206-216.
• [16]Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003, 13:741-757.
• [17]Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG: Distinct haplotype profiles and strong linkage disequilibriumat the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002, 12:437-450.
• [18]Rongrong L: The role of multidrug resistance gene 1 polymorphism to prognosis of adult acute lymphoblastic leukemia patients. Central South University 2008, 5:1-48.
• [19]Zhi-zhuo D: The singnificance of the expression of the CYP3A5 and MDRl genetic polymorphism in childhood acute lymphoblastic leukemia. Journal Of Clinical Pediatrics 2011, 29(3):283-289.
• [20]Jamroziak KM, Lłynarski W, Balcerc Zak E, Mistygacz M, Trelin Ska J, Mirowski M, Bodalski J, Robak T: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol Eur J Haematol 2004, 72:314-321.
• [21]Evelia L-U, Melva G-A, Macías-Gómez NM, Valeria P-L, Jorge D-G, María De La Luz A-M, Miriam P-P, Patricio B-N, Dinorah R-D, Moreno-Ortiz JM, Jorge P-S, Juan Pablo M-E: MDR1 C3435T Polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals. Human Biol 2008, 80(4):449-455.
• [22]Agnes F, Semsei Daniel J, Erdelyi I, Ungvari E, Kamory Be la C, Hajnalka A, Attila T, Edit C, Andras F, Kovacs GT, Csaba S: Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leukemia Res 2008, 32:1214-1220.
• [23]Vibeke A, Lene A, Dorte J, Østergaard M, Sæbø M, Hamfjord J, Kure E, Vogel U: Polymorphisms in the xenobiotic transporter multidrug resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 2009, 10:10-18.
• [24]Campa D, Sainz J, Pardini B, Vodickova L, Naccarati A, Rudolph A, Novotny J, Forsti A, Buch S, von Witigo S, Schafmayer C, Volzke H, Hoffmeister M, Frank B, Barale R, Hemminki K, Hampe J, Chang-Claude J, Brenner H, Vodicka P, Canzian F: A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. PLoS ONE 2012, 7(3):e32784.
• [25]Potocnik U, Glava D, Dean M: Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancergencyto 2008, 183:28-34.
• [26]Mhaidat NM, Alshogran OY, Khabour OF, Alzoubi KH, Matalka II, Haddadin WJ, Mahasneh IO, Aldaher AN: Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin’s Lymphoma. J Exper Clin Cancer Res 2011, 30(68):1-8.
• [27]Bae S-Y, Sun-Keun C, Kyung-Rae K, Chang-Shin P, Sung-Keun L, Hyung-Keun R, Dong-Woon S, Jae-Eun P, Ze-Hong W, Ju-Hee K: Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci 2006, 97:774-779.
• [28]Khedri A, Nejat-Shokouhi A, Salek R, Esmaeili H, Mokhtarifar A, Heravi RE, Tatari F, Behravan J, Miladpour B, Shahireh Omidvar SO: Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep 2011, 38:2939-2943.
• [29]Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Białecka M, Gornik W, Lubinski J: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 2005, 61:389-394.
• [30]Komoto C, Nakamura T, Sakaeda T, Deanna I: MDR1 Haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 2006, 21(2):126-132.
• [31]Lee B-I, Kyu-Yong C, Kang-Moon L, Woo-Chul C, Byung-Wook K, Hwang C, Se-Hyun C, Hyong-Ju K, Jin-Sun L, Myung-Seok K, Hiun-Suk C, In-Sik C: Is C3435T polymorphism of MDR1 related to inflammatory bowel disease or colorectal cancer in Korean? 2006, 47:22-29.
• [32]Osswald E, Andreas J, Laschinski G, Arjomand-Nahad F, Uwe M, Kirchheiner J, Gerloff T, Meisel C, Mrozikiewicz PM, Chernov J, Roots I, Köpke K: Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol 2007, 63:9-16.
• [33]Panczyk M, Ewa B, Sylwester P, Krzysztof J, Grażyna P-W, Mirowski M: ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis 2009, 24:895-905.
• [34]Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, Toncheva D, Oellerich M, von Ahsen N: No association between MDR1 (ABCB1) 2677G > T and 3435C > T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 2008, 134:317-322.
• [35]Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schonfels W, Hampe J, Schafmayer C, Volzke H, Frank B, Brenner H, Forsti A, Hemminki K, Chang-Claude J: Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocrine-Related Cancer 2011, 18:265-276.
• [36]Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 2010, 10:62-69.
• [37]Taheri M, Mahjoubi1 F, Omranipour R: Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 2010, 9(1):34-40.
• [38]Tatari F, Roham S, Fatemeh M, Azam K, Behravan J: Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA and Cell Biol 2009, 28(5):259-263.
• [39]George J, Kadambari D, Srinivasan K, Adithan C, Soya Sisy S, Elangovan S: A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 2009, 9(3):161-165.
• [40]Henriquez-Hernandez LA, Murias Rosales A, Hernandez Gonzalez A, Cabrera De Leon A, Diaz-Chico BN, Mori De Santiago M, Fernandez Perez L: Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case–control study. Oncol Reports 2009, 22:1425-1433.
• [41]Nordgard SH, Ritchie MD, Jensrud SD, Motsinger AA, Alnæs GIG, Lemmon G, Marianne B, Geisler S, Moore JH, Lønning PE, Børresen-Dale AL, Kristensen VN: ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics Genomics 2007, 17:127-136.
• [42]Turgut S, Arzu Y, Raziye K, Gunfer T: MDR1 C3435T Polymorphism in patients with breast cancer. Archives Med Res 2007, 38:539-544.
• [43]Wu H, Kang H, Liu Y, Tong W, Duo L, Xiuli Y, Minqiong L, Weifan Y, Haishan Z, Desheng H, Xianzheng S, Enhua W, Minjie W: Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol 2012, 138:1449-1462.
• [44]Sabahi Z, Salek R, Heravi RE, Mosaffa F, Avanaki ZJ, Behravan J: Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. 2010, 47(3):317-321.
• [45]Sugimoto M, Takahisa F, Naohito S, Chise K, Masafumi N, Mihoko Y, Mutsuhiro I, Haruhiko S, Takashi I, Akira H: MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese. Life Sci 2008, 83:301-304.
• [46]Tahara T, Tomiyasu A, Tomoyuki S, Ichiro H, Hiroshi N: Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol 2007, 22:1678-1682.
• [47]Mrozikiewicz PM, Seremak-mrozikiewicz A, Semczuk A, Landt O, Breborowicz GH, Drews K: The significance of C3435T point mutation of the MDR1 gene in endometrial cancer. Int J Gynecol Cancer 2007, 17:705-734.
• [48]Gemignani F, Landi S, Neonilia S-D, Zaridze D, Jolanta L, Rudnai P, Eleonora F, Dana M, Lenka F, Vladimir J, Vladimir B, Valerie G, Gioia-Patricola L, Ilaria B, Barale R, Canzian F, Hall J, Boffetta P, Hung RJ, Brennan P: Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007, 28(6):1287-1293.
• [49]Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund S, Kroemer HK, Warzok RW, Cascorbi I: Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007, 7:56-65.
• [50]Jamroziak K, Ewa B, Cebula B, Janus A, Mirowski M, Tadeusz R: No influence of 3435C > T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells. Ther Drug Monit 2006, 28(28):707-711.
• [51]Miller KL, Kelsey KT, Wiencke JK, Moghadassi M, Rei M, Mei L, Wrensch M: The C3435T Polymorphism of MDR1 and Susceptibility to Adult Glioma. Neuroepidemiol 2005, 25:85-90.
• [52]Jamroziak K, Ewa B, Smolewski P, Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szmigielska-Kapon A, Mirowski M, Bates SE, Tadeusz R: MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacological Reports 2006, 58:720-728.
• [53]Siegsmund M, Ulrich B, Elke Scha F, Gregor W, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Uwe R, Reinhold K, Sven H, Hiltrud B: Association of the P-glycoprotein transporter MDR1 C3435T polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002, 13:1847-1854.
• [54]Gervasini G, Carrillo JA, Montserrat G, Carmen San J, Cabanillas A, Benitez J: Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/a gene polymorphism is associated with high risk of lung cancer. Cancer 2006, 107(12):2850-2857.
• [55]Sam SS, Vinod T, Kumaran S: Kanipakapatanam Sathyanarayana Reddy, Gopalakrishnan Surianarayananc and Adithan Chandrasekaran. ABCB1 genetic polymorphism and risk of upper aerodigestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population. Pharmacogenetics Genomics 2007, 17:861-866.
• [56]Jamroziak K, Ewa B, Calka K, Piaskowski S, Urbanska-Rys H, Salagack A, Mirowski M, Robak T: Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leukemia Res 2009, 33:332-335.
• [57]Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W Jr, Vilela G, Zanette DL, Ferry C, Larghero J, Devergie A, Ribaud P, Skvortsova Y, Tamouza R, Gluckman E, Socie G, Zago MA: Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009, 23:545-556.
• [58]Drain S, Mark A, Catherwood NO, Galligan LI, Maeve R, Hodkinson C, Drake MB, Kettle PJ, Curly Morris TCM, Alexander DH: ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leukemia Lymphoma 2009, 50(4):566-570.
• [59]Penna G, Allegra A, Alonci A, Aguennouz M, Garufi A, Cannavo A, Gerace D, Alibrandi A, Musolino C: MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol 2011, 28:1549-1554.
• [60]The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk: Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 2010, 120:727-736.
• [61]Chang H, Sun Young R, Hei-Cheul J, Chong Kun I, Sung Hoon N, Jin Ju K, Hyun Cheol C: Association of the ABCB1 3435C > T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Reports 2010, 23:271-278.
• [62]Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadharao D, Senthil R: Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pacific J Cancer Prev 2010, 11:1063-1066.